These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32049889)

  • 1. Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?
    van Maarseveen EM; van der Meer R; Neef C; Heijerman HGM; Touw DJ
    Ther Drug Monit; 2020 Aug; 42(4):595-599. PubMed ID: 32049889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.
    Prayle AP; Jain K; Touw DJ; Koch BC; Knox AJ; Watson A; Smyth AR
    J Cyst Fibros; 2016 Jul; 15(4):510-7. PubMed ID: 26282839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Relationship between FEV
    Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
    Aminimanizani A; Beringer PM; Kang J; Tsang L; Jelliffe RW; Shapiro BJ
    J Antimicrob Chemother; 2002 Oct; 50(4):553-9. PubMed ID: 12356801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    Antimicrob Agents Chemother; 2013 Oct; 57(10):5175-7. PubMed ID: 23896470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Bhatt J
    Cochrane Database Syst Rev; 2010 Jan; (1):CD002009. PubMed ID: 20091528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J; Cranswick N
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
    Albright JC; Houck AP; Pettit RS
    Pediatr Pulmonol; 2020 Oct; 55(10):2662-2666. PubMed ID: 32568427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
    Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL
    J Antimicrob Chemother; 2017 Jan; 72(1):254-260. PubMed ID: 27585963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Bhatt J
    Cochrane Database Syst Rev; 2012 Feb; (2):CD002009. PubMed ID: 22336782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
    Brigg Turner R; Elbarbry F; Biondo L
    J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
    Beringer PM; Vinks AA; Jelliffe RW; Shapiro BJ
    Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis.
    Sherwin CM; Zobell JT; Stockmann C; McCrory BE; Wisdom M; Young DC; Olson J; Ampofo K; Spigarelli MG
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):71-9. PubMed ID: 24395072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.